Health Care · Pharmaceutical Preparations

BIOA BioAge Labs, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 170994149 filings
Russell 2000

BIOA at a glance

BioAge Labs, Inc. (BIOA, SEC CIK 1709941) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as July 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), BioAge Labs, Inc. (BIOA) reported revenue of $9.0 million and a net loss of $80.6 million. Diluted EPS was -$2.24.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding BioAge Labs, Inc. (BIOA) shares worth $91.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Barton Shane on June 30, 2026 of 20,216 shares at $25.19 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$9.0M
10-K XBRL
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
26 funds
$91.6M · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Collaboration revenue $0.3M, down 85% YoY from $2.1M, reflecting a $1.7M Novartis catch-up adjustment
  • Net loss $33.5M vs $20.2M YoY, with operating expenses $37.7M vs $25.2M
  • BGE-102 R&D spending $17.8M vs $4.7M, the strongest program; other programs $4.4M vs $7.7M
  • Cash, equivalents and marketable securities $352.3M; operating cash used $74.3M through nine months
  • Funding expected through 2029; QUELL-CV topline data anticipated fourth quarter 2026, with additional capital needs and clinical risks remaining

Risk Factors

  • Newly added regulatory risk: BIOSECURE Act, triggered by WuXi AppTec’s June 8, 2026 designation on the 1260H List
  • Most material update: QUELL-DME began dosing approximately 180 participants, including combination therapy with anti-VEGF
  • Near-term clinical risk: QUELL-CV topline data anticipated in fourth quarter of 2026, with hsCRP reduction potentially not translating into cardiovascular benefit
  • Financial risk: $352.3 million in cash, equivalents and marketable securities expected to fund operations through 2029
  • Manufacturing risk: China and India suppliers exposed to tariffs, trade restrictions and supply-chain disruption

AI summary of the BIOA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Press release attached as Exhibit 99.1, providing the substantive financial details

Item EX-99.1: Item EX-99.1

  • QUELL-CV fully enrolled at approximately 160 participants, with 30 mg, 60 mg, and 90 mg doses; topline data expected Q4 2026
  • QUELL-DME Phase 2 dosed its first participant, targeting approximately 180 patients; topline results expected in H2 2027
Filed Oct 2, 2026Full analysis →

Item 8.01: Other Events

  • First participant dosed in QUELL-DME, advancing BGE-102 into a randomized Phase 2 diabetic macular edema study
  • Approximately 180 participants across three arms, testing BGE-102 monotherapy and combination use with anti-VEGF therapy
Filed Aug 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 2026 net loss widened to $26.1M from $21.6M, while R&D rose to $24.4M as BGE-102 trials advanced
  • QUELL-CV Phase 2 enrolled its first participant, testing 30 mg, 60 mg, and 90 mg doses in approximately 160 adults

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Investor-relevant figures and management commentary contained in Exhibit 99.1 press release

AI summaries of BIOA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BIOA

Don't miss the next BIOA filing

  • Alerts as it files. A push when BIOA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BIOA, by share count.
  • Ask anything. An AI agent that reads every BIOA filing and answers with sources.

BIOA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Barton ShaneMJun 30, 2026-
Barton ShaneMJun 30, 2026-
Barton ShaneMJun 30, 2026-
Barton ShaneMJun 30, 2026-
Barton ShaneMJun 30, 2026$4.38
Barton ShaneMJun 30, 2026$4.30
Barton ShaneMJun 30, 2026$8.39
Barton ShaneSellJun 30, 2026$25.19

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$0$9.0M
Operating Income-$48.4M-$78.2M-$92.8M
Net Income--$71.1M-$80.6M
Op. Margin---1031.5%
Net Margin---896.1%
Balance Sheet
Total Assets$25.9M$358.2M$294.9M
Equity-$173.4M$323.1M$272.1M
ROE--22.0%-29.6%
Per Share
EPS-$-6.63$-2.24
Cash Flow
Operating CF--$51.5M-$81.6M
CapEx$166K$366K$719K

Source: XBRL data in BioAge Labs, Inc. (BIOA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BIOA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BIOA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$91.6M
Q2 202627$239.8M
Q1 202625$140.5M
Q4 202523$74.5M
Q3 202521$28.1M
Q2 202520$16.7M
Q1 202512$4.1M
Q4 20248$3.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 162 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BIOA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KOct 2, 2026Analysis-
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
4Jul 1, 2026--
8-KJun 12, 2026Analysis-
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
8-KMay 8, 2026Analysis
10-QMay 8, 2026Analysis
SC 13GApr 27, 2026-
4Apr 24, 2026--
4Apr 3, 2026--
10-KMar 24, 2026-
8-KMar 24, 2026--
4Mar 3, 2026--
4Feb 19, 2026-
4Feb 19, 2026-
4Feb 19, 2026-
4Feb 19, 2026-

Related Health Care companies

All Health Care →

BIOA SEC filings: frequently asked questions

Which institutions hold BIOA stock?

As of September 30, 2026, the largest BioAge Labs, Inc. (BIOA) holders among the 13F filers tracked by SignalX were BlackRock ($25.1 million), Vanguard Capital Management LLC ($11.5 million), State Street Corp ($9.6 million), D.E. Shaw & Co ($8.2 million), JPMorgan Chase & Co ($5.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BIOA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), BioAge Labs, Inc. (BIOA) reported revenue of $9.0 million and a net loss of $80.6 million. Diluted EPS was -$2.24. The figures come from the XBRL data in the 10-K.

What did BIOA report in its latest 8-K?

BioAge Labs, Inc. (BIOA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest BIOA SEC filings?

BioAge Labs, Inc. (BIOA) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on July 1, 2026.

What is BIOA's SEC CIK number?

BioAge Labs, Inc. (BIOA)'s SEC Central Index Key (CIK) is 1709941. EDGAR lists every BIOA filing under that number.

Ask anything about BIOA

The research agent reads BIOA's filings, financials, insider trades and 13F holders, then answers with sources.